Jackie has over 15 years of life sciences experience, including science, research, business development and venture investing. She joined Abingworth in November 2018 and works with the team in the Boston, London and Menlo Park offices to source and evaluate new opportunities and support existing venture investments. Jackie is active in our company creation efforts and is responsible for a number of emerging newcos currently in stealth mode. Jackie represents Abingworth on the boards of Atsena and Nido and is an observer on the Anjarium and Glycomine boards.
Previously, Jackie was a Senior Associate at SVHealth Investors. She was formerly in the Business Development Group at Genentech with primary responsibility for partnering activities in neuroscience. Her transactions span a broad spectrum of deal structures and therapeutic areas, including technology and platform in-licenses, asset out-licenses and research collaborations. Jackie has a PhD in Neuroscience from Stanford School of Medicine and an MBA from Stanford Graduate School of Business.